Stay updated on ATHENA Clinical Trial: Rucaparib+Nivolumab in Ovarian Cancer

Sign up to get notified when there's something new on the ATHENA Clinical Trial: Rucaparib+Nivolumab in Ovarian Cancer page.
Latest website image capture
Clouds background image

Latest updates to the ATHENA Clinical Trial: Rucaparib+Nivolumab in Ovarian Cancer page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a Phase 3 clinical trial evaluating rucaparib and nivolumab as maintenance treatment for ovarian cancer patients following response to front-line platinum-based chemotherapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:55:51.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion in the study. Previously, this section had no information.
    Difference
    7%
    Check dated 2024-05-22T21:29:34.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:43:50.000Z thumbnail image

Stay in the know with updates to ATHENA Clinical Trial: Rucaparib+Nivolumab in Ovarian Cancer

Enter your email address, and we'll notify you when there's something new on the ATHENA Clinical Trial: Rucaparib+Nivolumab in Ovarian Cancer page.